A Mab A Case Study In Bioprocess Development Here

principles can be applied to develop a monoclonal antibody (mAb)

The outcome was a robust run, where the culture achieved a final titer of 4.5 g/L —a benchmark that makes the manufacturing economically viable. A Mab A Case Study In Bioprocess Development

Reduced the transition from pilot to clinical scale by four months. Robustness: principles can be applied to develop a monoclonal

The production process included a dedicated after elution. The process begins by establishing the "end goal"

The process begins by establishing the "end goal" before any manufacturing starts. International Society for Pharmaceutical Engineering (ISPE) Target Product Profile (TPP):

The process begins by defining the , which outlines the desired clinical safety and efficacy of the antibody. From this, scientists identify Critical Quality Attributes (CQAs) —physical, chemical, or biological properties that must be within an appropriate limit to ensure product quality.

Low pH hold (pH 3.6 for 60 minutes) was used. But with A Mab’s sensitivity, they optimized to pH 3.7 for exactly 30 minutes – no longer, no shorter. Validation showed >4 log reduction of model virus (xMuLV).